Atlas Trials

Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE)

Clinical trial NCT05308966 · COMPLETED

Trial details

NCT number
NCT05308966
Sponsor
Groupe Francais De Pneumo-Cancerologie
Status
COMPLETED
Study type
OBSERVATIONAL
Malignant Pleural MesotheliomaUnresectable Malignant Neoplasm
Start date
2022-05-03
Primary completion
2025-08-27
Enrollment
204

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.